TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2020-10-16
$72.64
-0.68 (-0.93%)
last quote
Want the full multi-source brief on TARS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$72.64
High
$75.20
Low
$70.39
Previous close
$73.32
Fundamentals
Market cap
$3.58B
P/E (TTM)
—
P/S (TTM)
5.91x
P/B
10.12x
Gross margin
93.28%
Operating margin
-8.00%
Net margin
-7.67%
Rev growth (YoY)
105.17%
EPS growth (YoY)
—
ROE
-13.53%
52W high
$91.53
52W low
$53.89
Beta
0.40x
Industry peers
by market cap
Recent SEC filings
CIK 1819790filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 9h
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions. XDEMVY net product sales
ChartMill · 12h
Tarsus Pharmaceuticals (NASDAQ:TARS) Posts XDEMVY Beat but Acquisition Costs Weigh on Results
Tarsus Q3: XDEMVY sales beat at $194.6M and adjusted loss narrowed, but acquisition charges drove a huge GAAP loss and shares slipped.
Yahoo · 12h
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha · 14h
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call November 3, 2026 4:30 PM ESTCompany ParticipantsDavid Nakasone - Head of Investor RelationsBobak...
Yahoo · 15h
Tarsus Reports Third Quarter 2026 Financial Results
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov.
Yahoo · 1d
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SeekingAlpha · 3d
My 'Eye' Is On Tarsus Pharmaceuticals
Tarsus Pharmaceuticals may be undervalued after its pullback, with Xdemvy growth, pipeline upside, and key catalysts ahead. Read the full analysis here on TARS stock.
Yahoo · 5d
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial